Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1

American Journal of Ophthalmology

Volumn 136, Issue 3, 2003, Pages 407-418

  Blinder, Kevin J ^b   Bradley, Shannon ^a   Bressler, Neil M ^b   Bressler, Susan B ^b   Donati, Guy ^b   Hao, Yong ^a   Ma, Colin ^b   Menchini, Ugo ^b   Miller, Joan ^b   Potter, Michael J ^b   Constantin Pournaras, J ^b   Reaves, Al ^a   Rosenfeld, Philip J ^b   Andrew Strong, H ^a   Stur, Michael ^b   Su, Xiang Yao ^a   Virgili, Gianni ^b  

^a QLT Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EYE INJURY; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PHOTODYNAMIC THERAPY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0041326404     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/S0002-9394(03)00223-X     Document Type: Article

References (11)

1. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
2. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 2001;119:198-207.
3. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial—VIP report no. 1. Ophthalmology 2001;108:841-852.
4. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin In Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-560.
5. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18.
6. American Academy of Ophthalmology Retina Panel Preferred practice pattern: age-related macular degeneration. October 2001. Available at: http://www.aao.org. Accessed May 21, 2002.
7. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes—TAP report no. 3. Arch Ophthalmol 2002;120: 1443-1454.
8. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report number 1. Arch Ophthalmol 1985;103:1796-1806.
9. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000;84:244-250.
10. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-1231.
11. SAS Institute Inc. SAS/STAT user’s guide, version 6, 4th ed. Vol 2. Cary, NC: SAS Institute, 1989:891-996.